[go: up one dir, main page]

HK1196039A - Performance enhancing compositions and methods of use - Google Patents

Performance enhancing compositions and methods of use Download PDF

Info

Publication number
HK1196039A
HK1196039A HK14108790.9A HK14108790A HK1196039A HK 1196039 A HK1196039 A HK 1196039A HK 14108790 A HK14108790 A HK 14108790A HK 1196039 A HK1196039 A HK 1196039A
Authority
HK
Hong Kong
Prior art keywords
methods
performance enhancing
microgram
day
enhancing compositions
Prior art date
Application number
HK14108790.9A
Other languages
Chinese (zh)
Inventor
Jan Remmereit
Original Assignee
Life Science Nutrition As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Life Science Nutrition As filed Critical Life Science Nutrition As
Publication of HK1196039A publication Critical patent/HK1196039A/en

Links

Abstract

The present invention relates to composition containing sialic acids or precursors, and their use to improve performance-related and social parameters in mammals, particularly humans and horses. The daily dosage is preferably selected from the group consisting of 1 microgram to 100 mg/day, 100 microgram to 20 mg/day, and 200 microgram to 10 mg/day.
HK14108790.9A 2011-05-05 2012-05-04 Performance enhancing compositions and methods of use HK1196039A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61/482,655 2011-05-05

Publications (1)

Publication Number Publication Date
HK1196039A true HK1196039A (en) 2014-12-05

Family

ID=

Similar Documents

Publication Publication Date Title
MY159630A (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
CA2818187C (en) Bromodomain inhibitors and uses thereof
CN104024227B8 (en) Crystal forms of compound for inhibiting proline hydroxylase activity and application thereof
EP3354640A3 (en) Mif inhibitors and their uses
MY164356A (en) Substituted 5-fluoro-1h-pyrazolopyridines and their use
MY188960A (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2013066835A3 (en) Compounds and methods
WO2013179307A3 (en) Stabilized pharmaceutical compositions of saxagliptin
CN102036649A8 (en) Arginine salts and their use in the treatment of oral diseases
MX340985B (en) N-heteroaryl compounds.
MX2013004759A (en) Oxime compounds as hdl-cholesterol raising agents.
MY156275A (en) Compositions comprising tramadol and celecoxib in the treatment of pain
EA201400537A1 (en) 18-METHYL-6,7-METHYLENE-3-OXO-17-PREGN-4-EN-21,17β-CARBOLACONES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE INDICATED COMPOUNDS AND THEIR APPLICATION IN THE TREATMENT OF ENDOMETRIOZA
EA201101214A1 (en) POLYENE COMBINATION COMPOSITIONS
WO2013061004A8 (en) Novel disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
WO2009130616A3 (en) Improved tlr3 agonist compositions
MX342947B (en) Treatment of type 2 diabetes.
PH12013500371A1 (en) Therapeutic agent for pain
IN2012DN00763A (en)
HK1201067A1 (en) Sialic acid analogs
EP3795145A3 (en) Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol
EP3456837A3 (en) Decorin compositions and use thereof
CA2834182C (en) Honey composition with l-alanyl-l-glutamine
HK1196039A (en) Performance enhancing compositions and methods of use